Increasing the Therapeutic Index of a Small Molecule as Precision ADCs: What Have we Learnt so Far?

• Designing DACs to be a more targeted to oncogenic drivers versus traditional small molecule inhibitors
• Discussing initial proof-of-concept case studies for DACs
• Collaboration potential between antibody engineering and protein degradation companies

Speakers:

Yue Xiong

Chief Scientific Officer

Cullgen Inc.

Greg Dwyer

Senior Vice President, Business Development

Orum Therapeutics, Inc.

Jesse Chen

President & Chief Executive Officer

Fortitude Biomedicines

Jason Kantor

Chief Business Officer

Nurix Therapeutics, Inc.